-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
Evolving Standards of Care
-
COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events
Industry Supported
The COCOON trial compared SOC with prophylactic management for treatment-related dermatologic events with amivantamab plus lazertinib. In this Q&A, Dr. Martin F. Dietrich explains the prophylactic regimen’s impact on effects of the skin, scalp, and nails. APP Alyson Singer offers best practices for patient education.
-
Impact of Clinical Pathways on Lung Cancer Management
Posted: February 2017 Q&A with with Ronan J. Kelly, MB BCh, MBA Q: What is the impetus for the development of clinical pathways? A: The incidence of cancer in the US is expected to increase by 45% in the next 2 decades, from 1.6 million in 2010 to 2.3 million in 2030. Direct medical costs associated…
-
Drug Development in the 21st Century
Posted: February 2017 By Lori Alexander, MTPW, ELS, MWC Drug development has become a biomarker- driven process, necessitating new approaches and clinical trial designs. Speakers addressed these issues in the WCLC session “Anticancer Drug Development in the 21st Century.” Former IASLC President Tony Mok, MD, of Chinese University of Hong Kong, explained that the two…
-
NICE: It Takes Two to Tango
By Sanjay Popat, FRCP, PhD United Kingdom Healthcare System The United Kingdom (UK) has a unique healthcare system: the National Health Service (NHS), a publicly funded, singlepayer system. Founded by the Labour government in 1948, its unique identity is constitutionally defined as a comprehensive service delivered to all, based on clinical need and not on…
-
What’s New from the 2016 ESMO Clinical Guidelines
By Matteo Giaj Levra, MD, and Silvia Novello MD, PhD In September, the 2016 ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up of metastatic nonsmall cell lung cancer (NSCLC) were published. These guidelines outline many new recommendations updated from the 2014 version, following trends of innovation during the last 2 years in the field…
-
Update to the “Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors”
The College of American Pathologists (CAP), International Association for the Study of Lung Cancer (IASLC), and Association for Molecular Pathology (AMP) published online in April 2013 the original “Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors” in Archives of Pathology & Laboratory Medicine, Journal of Thoracic Oncology,…
-
National Comprehensive Cancer Network NSCLC Guideline Updates for 2016: Non-Small Cell Lung Cancer
By Erik J. MacLaren, PhD The table at right lists key updates to the National Comprehensive Cancer Network (NCCN) Guidelines for NSCLC as of February 2016. These guidelines are not determined solely by evidence, but also incorporate expert opinion and are subject to frequent updates. Recommendations by NCCN fall into 1 of 4 categories of…
View ILCN Archives
Provider Resources
Popular Articles